The Affiliated Yancheng Hospital, School of Medicine, Southeast University, Yancheng, Jiangsu Province, China.
Medicine (Baltimore). 2021 Jul 9;100(27):e26536. doi: 10.1097/MD.0000000000026536.
This meta-analysis aimed to synthesize randomized controlled trials to evaluate the effects of enhanced external counterpulsation (EECP) on exercise capacity and quality of life in patients with chronic heart failure (CHF).
Both English and Chinese databases were searched from their inception to June 30, 2020 (PubMed, EMBASE, Cochrane Library, CINAHL (EBSCO), Web of Science for English publications and Chinese Biomedical Database, China National Knowledge Infrastructure, Wanfang Data for Chinese publication). Titles, abstracts, and full-text articles were screened against study inclusion criteria: randomized controlled trials studying EECP intervention for patients with CHF. The meta-analysis was conducted with Revman 5.3 or STATA 16.0.
Eight randomized controlled trials were included. EECP induced significant improvement in 6-min walking distance (WMD=84.79 m; 95% CI, 47.64 to 121.95; P < .00001). Moreover, EECP was beneficial for left ventricular ejection fraction (SMD = 0.64; 95% CI,0.29 to 1.00; P = .0004), and N-terminal pro brain natriuretic peptide (SMD = -0.61; 95%CI, -1.20 to -0.01; P = 0.04).However, compared with the control groups, EECP did not significantly reduce the Minnesota Living with Heart Failure Questionnaire scores(WMD, -9.28; 95% CI, -19.30 to 0.75; P = 0.07).
Despite heterogeneity and risk of bias, this meta-analysis confirms that EECP can improve exercise capacity in CHF patients, especially the elderly. However, the evidence that EECP improves the quality of life in patients with CHF is still insufficient. More and larger well-designed randomized controlled trials are still warranted.
PROSPERO registration no. CRD 42020188848.
本荟萃分析旨在综合随机对照试验,评估增强型体外反搏(EECP)对慢性心力衰竭(CHF)患者运动能力和生活质量的影响。
从建库至 2020 年 6 月 30 日,检索了英文和中文数据库(PubMed、EMBASE、Cochrane 图书馆、CINAHL(EBSCO)、Web of Science 检索英文文献,中国生物医学文献数据库、中国知网、万方数据检索中文文献)。筛选出纳入研究标准的标题、摘要和全文文章:EECP 干预 CHF 患者的随机对照试验。使用 Revman 5.3 或 STATA 16.0 进行荟萃分析。
纳入 8 项随机对照试验。EECP 可显著改善 6 分钟步行距离(WMD=84.79 m;95%CI,47.64 至 121.95;P<0.00001)。此外,EECP 有利于左心室射血分数(SMD=0.64;95%CI,0.29 至 1.00;P=0.0004)和 N 端脑利钠肽前体(SMD=-0.61;95%CI,-1.20 至-0.01;P=0.04)。然而,与对照组相比,EECP 对明尼苏达州心力衰竭生活质量问卷评分的降低作用不明显(WMD,-9.28;95%CI,-19.30 至 0.75;P=0.07)。
尽管存在异质性和偏倚风险,但本荟萃分析证实,EECP 可改善 CHF 患者的运动能力,特别是老年患者。然而,EECP 改善 CHF 患者生活质量的证据仍不足,仍需要更多、更大的精心设计的随机对照试验。
PROSPERO 注册号 CRD 42020188848。